• Dovitinib (TKI-258): Multitarget RTK Inhibition in Cancer Re

  2026-05-17

  Dovitinib (TKI-258) is a multitargeted receptor tyrosine kinase inhibitor with potent nanomolar efficacy against FLT3, c-Kit, FGFR1/3, and VEGFRs. It induces apoptosis and suppresses proliferation in RTK-driven cancer cell lines. This article details its mechanisms, benchmarks, and optimal integration into experimental workflows.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-16

  Liang Xue et al. provide compelling evidence that PPARγ activation, particularly via pioglitazone, regulates macrophage polarization through the STAT-1/STAT-6 pathways, attenuating inflammation in dextran sulfate sodium (DSS)-induced inflammatory bowel disease (IBD) models. Their integrated in vitro and in vivo approach advances mechanistic understanding relevant for translational inflammation and metabolic disorder research.

• Fluo-4 AM in Podocyte Calcium Signaling: Beyond Imaging

  2026-05-15

  Explore how Fluo-4 AM, a leading fluorescent calcium indicator, enables advanced interrogation of intracellular calcium dynamics in podocyte research—delivering unique mechanistic insight into diabetic nephropathy and calcium signaling beyond standard imaging workflows.

• Anti-ROR1 Antibody (Zilovertamab): Advanced Protocols & Nove

  2026-05-15

  Explore the advanced applications and experimental design strategies enabled by Anti-ROR1 Antibody (Zilovertamab) in cancer research. This cornerstone article offers unique, protocol-level guidance and integrates mechanistic insights for optimized Wnt5a-induced ROR1 signaling inhibition.

• Graphene Film Triggers Apoptosis and Hypoxic Stress in Melan

  2026-05-14

  This study demonstrates that graphene film induces apoptosis and hypoxic stress in melanoma cells via caspase-dependent and -independent mitochondrial pathways. The findings clarify the molecular mechanisms of graphene-induced cell death and suggest new approaches for melanoma therapy targeting mitochondria-mediated apoptosis.

• 5-Methyl-CTP: Redefining mRNA Synthesis for Durable Vaccines

  2026-05-14

  Discover how 5-Methyl-CTP, a 5-methyl modified cytidine triphosphate, empowers advanced mRNA synthesis with unprecedented stability and translational efficiency. This deep-dive explores new insights from recent vaccine breakthroughs and practical protocol guidance.

• Okadaic Acid (A4540): Protocols for Protein Phosphatase 1 In

  2026-05-13

  Okadaic acid is a validated, nanomolar-range protein phosphatase 1 inhibitor, primarily used to dissect phosphorylation-dependent signaling and apoptosis mechanisms in cell and biochemical assays. It is best suited for studies requiring precise control of PP1 and PP2A activity; it is not recommended for exploratory applications outside phosphatase-driven pathway analysis.

• Praeruptorin A Inhibits HCC Metastasis via ERK/MMP1 Pathway

  2026-05-13

  This paper demonstrates that Praeruptorin A, an angular pyranocoumarin compound, inhibits the migration and invasion of human hepatocellular carcinoma (HCC) cells by downregulating MMP1 through activation of the ERK1/2 pathway. The findings highlight Praeruptorin A’s specific anti-metastatic mechanism in HCC models without compromising cell viability, positioning it as a promising research tool for targeted cancer metastasis studies.

• GLT-1 Upregulation Reduces Neuronal Death via CB1-CREB Pathw

  2026-05-12

  This study uncovers a mechanistic link between endocannabinoid-induced CB1 activation and reduced astrocytic GLT-1 expression after traumatic brain injury (TBI), leading to increased neuronal apoptosis and cognitive deficits. Upregulation of GLT-1 mitigates these effects by suppressing the CB1-CREB pathway, highlighting a potential therapeutic strategy for TBI.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells

  2026-05-12

  This paper elucidates how Epstein-Barr virus (EBV) drives dedifferentiation in nasopharyngeal carcinoma (NPC) via epigenetic repression of CEBPA, promoting cellular plasticity and therapy resistance. The study demonstrates that histone deacetylase (HDAC) inhibition restores differentiation, providing a mechanistic basis and preclinical support for differentiation therapy in solid tumors.

• LY2886721: Translational Insights for BACE Inhibition in AD

  2026-05-11

  Explore the translational potential of LY2886721, a potent BACE inhibitor, in Alzheimer's disease research. This article uniquely dissects dose-response relationships, synaptic safety, and protocol optimization for amyloid beta reduction.

• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-05-11

  This study re-examines the pharmacological selectivity of the spider toxin v-Agatoxin-IVA, revealing its low-affinity blockade of neuronal N-type calcium channels alongside its established high-affinity inhibition of P-type channels. The findings refine our understanding of calcium channel classification and the interpretation of toxin-based assays in neurophysiological research.

• Reliable Cell Assays with Recombinant Human Oncostatin M (E.

  2026-05-10

  This article addresses persistent challenges in cell-based assays, focusing on how Recombinant Human Oncostatin M (E.coli, Tag Free, Lyophilized) (SKU P1045) delivers reproducibility and data integrity for critical endpoints such as cell proliferation and cytokine induction. Scenario-driven Q&A blocks equip researchers with workflow solutions, protocol tips, and evidence-backed vendor guidance. APExBIO's tag-free, lyophilized cytokine stands out for its purity, activity, and compatibility across research models.

• Cinoxacin in Translational Research: Mechanistic Power & Str

  2026-05-09

  This article delivers a strategic, evidence-driven exploration of Cinoxacin—a quinolone antibiotic—emphasizing its mechanistic underpinnings, validated research use, and future directions for translational studies in Gram-negative infection and antibiotic resistance. By bridging biological rationale with protocol precision and clinical context, it guides researchers in maximizing Cinoxacin’s impact beyond standard overviews, leveraging APExBIO’s trusted supply and integrating learnings from the latest literature.

• Epalrestat: Bridging Polyol Pathway Inhibition and Cancer Me

  2026-05-09

  This thought-leadership article explores the expanding translational research utility of Epalrestat, a high-purity aldose reductase inhibitor, at the intersection of diabetic complication research, neurodegeneration, and emerging cancer metabolism strategies. Integrating mechanistic insights into polyol pathway inhibition, KEAP1/Nrf2 activation, and recent evidence linking fructose metabolism to tumor malignancy, we provide actionable guidance for researchers seeking to leverage Epalrestat in advanced models of disease. The article highlights protocol best practices, competitive positioning, and a forward-looking outlook on next-generation experimental design.

408 records 15/28 page Previous Next First page 上5页 1112131415 下5页 Last page